Illumina: Q2 Earnings Insights

Shares of Illumina ILMN moved lower in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 201.61% over the past year to $1.87, which beat the estimate of $1.35.

Revenue of $1,126,000,000 up by 77.88% year over year, which beat the estimate of $1,010,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $6.30 and $6.50.

The upcoming fiscal year's revenue expected to be between $4,275,000,000 and $4,340,000,000.

Details Of The Call

Date: Aug 05, 2021

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.illumina.com%2F&eventid=3193061&sessionid=1&key=77F2A401A8737539C9DD57C2F340E743&regTag=&V2=false&sourcepage=register

Technicals

52-week high: $555.77

52-week low: $260.42

Price action over last quarter: Up 28.35%

Company Description

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.